These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 27120009)
1. Clinical characteristics, beliefs, and coping strategies among older patients with overactive bladder. Blasco P; Valdivia MI; Oña MR; Roset M; Mora AM; Hernández M Neurourol Urodyn; 2017 Mar; 36(3):774-779. PubMed ID: 27120009 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761 [TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668 [TBL] [Abstract][Full Text] [Related]
4. Correlation between psychological stress levels and the severity of overactive bladder symptoms. Lai H; Gardner V; Vetter J; Andriole GL BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525 [TBL] [Abstract][Full Text] [Related]
5. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358 [TBL] [Abstract][Full Text] [Related]
6. Impact of daily number of urgency urinary incontinence episodes on overactive bladder patient reported outcomes. Angulo JC; Brenes FJ; Lizarraga I; Rejas J; Trillo S; Ochayta D; Arumi D Actas Urol Esp; 2016 Apr; 40(3):173-82. PubMed ID: 26811022 [TBL] [Abstract][Full Text] [Related]
7. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
8. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS). Lee KS; Choo MS; Seo JT; Oh SJ; Kim HG; Ng K; Lee KJ; Tan JT; Kim JC Health Qual Life Outcomes; 2015 Jun; 13():89. PubMed ID: 26113125 [TBL] [Abstract][Full Text] [Related]
9. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Ricci JA; Baggish JS; Hunt TL; Stewart WF; Wein A; Herzog AR; Diokno AC Clin Ther; 2001 Aug; 23(8):1245-59. PubMed ID: 11558861 [TBL] [Abstract][Full Text] [Related]
10. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240 [TBL] [Abstract][Full Text] [Related]
11. Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder. Gotoh M; Kobayashi T; Sogabe K Neurourol Urodyn; 2015 Nov; 34(8):730-5. PubMed ID: 25212503 [TBL] [Abstract][Full Text] [Related]
12. Clinical and urodynamic impact of detrusor overactivity in women with overactive bladder. Jiménez-Cidre MA; López-Fando L; Mora AM; Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):221-227. PubMed ID: 30862379 [TBL] [Abstract][Full Text] [Related]
13. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Garely AD; Lucente V; Vapnek J; Smith N Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844 [TBL] [Abstract][Full Text] [Related]
15. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704 [TBL] [Abstract][Full Text] [Related]
16. Natural history of non-neurogenic overactive bladder and urinary incontinence over 5 years in community-dwelling older men: The concord health and aging in men project. Noguchi N; Chan L; Cumming RG; Blyth FM; Handelsman DJ; Waite LM; Le Couteur DG; Naganathan V Neurourol Urodyn; 2017 Feb; 36(2):443-448. PubMed ID: 26756291 [TBL] [Abstract][Full Text] [Related]
18. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714 [TBL] [Abstract][Full Text] [Related]
20. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q). Gotoh M; Kobayashi T; Sogabe K Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]